AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02691975
Drug: SHR3680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
Trial: NCT00834756
Drug: Azithromycin 600 mg Tablet
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 x 600mg, single-dose fasting
Trial: NCT00834756
Drug: Zithromax® 600 mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 600mg, single-dose fasting
Trial: NCT04239872
Drug: Calcium and fluoride mouthwash
RxNorm normalized name: sodium fluoride Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.
Trial: NCT01466868
Drug: MK2206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms.
Trial: NCT02485769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension
Trial: NCT02485769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (Modified Release)
Trial: NCT03541941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block
Trial: NCT03880487
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose and Multiple dose identical to active treatment but without KP-1199.
Trial: NCT03680911
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
Trial: NCT01792635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
Trial: NCT03287310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
Trial: NCT00804674
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01517893
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
Trial: NCT01517893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
Trial: NCT02839265
Drug: FLT3 Ligand Therapy (CDX-301)
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Arm 1 descriptions
Trial: NCT02591927
Drug: Glucose 5%
RxNorm normalized name: Glucose 5% Nursette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
Trial: NCT00296647
Drug: patch + lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
Trial: NCT01375257
Drug: Oral treatment with antibiotics for endocarditis
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02045550
Drug: Prospan Syrup
RxNorm normalized name: Irospan Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml twice daily for 4 weeks
Trial: NCT01540760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching MCAF5352A, multiple doses
Trial: NCT01375257
Drug: Guideline treatment with parenteral antibiotics
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02133196
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
Trial: NCT03700320
Drug: Standard of Care (SOC) Migraine Preventive Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
Trial: NCT04080947
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received matching-image placebo once daily at bedtime for 12 weeks.
Trial: NCT00956397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo TID x 10 days
Trial: NCT02601677
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
Trial: NCT02820155
Drug: RGN1016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
Trial: NCT02820155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
Trial: NCT02035085
Drug: CS-1000 labeled SVF cells
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
Trial: NCT04133623
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
Trial: NCT04133623
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
Trial: NCT00891982
Drug: CTGel/ BPO Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days.
Trial: NCT00891982
Drug: Soap Free Cleanser and CTGel
RxNorm normalized name: Aqua Glycolic Shampoo and Body Cleanser Soap Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days.
Trial: NCT01991990
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. infusion
Trial: NCT00003784
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003784
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003784
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03096730
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is intravenously administrated before anesthesia induction
Trial: NCT03096730
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is intravenously administrated
Trial: NCT03096730
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil is intravenously administrated
Trial: NCT00547170
Drug: Doxycycline pre-operatively
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)
Trial: NCT00547170
Drug: Doxycycline post-operatively
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)
Trial: NCT02388191
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 550 mg, oral, on day 1. Number of Cycles: 1
Trial: NCT00965185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00808171
Drug: Livopan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of oxygen and nitrous oxide 50%
Trial: NCT00808171
Drug: Livopan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equimolar mixture of N2O/O2
Trial: NCT03966365
Drug: PRO-122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* Route of administration: topical ophthalmic.
Trial: NCT03966365
Drug: Krytantek Ofteno®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * - 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* - Route of administration: topical ophthalmic.
Trial: NCT02139111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsule
Trial: NCT02139111
Drug: PRC-063 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25 mg capsule - active
Trial: NCT01840735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02139111
Drug: PRC-063 45 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 45 mg capsule - active
Trial: NCT02139111
Drug: PRC-063 70 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 70 mg capsule - active
Trial: NCT02139111
Drug: PRC-063 85 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 85 mg capsule - active
Trial: NCT01220362
Drug: Bupivacain 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacain 0.125%
Trial: NCT01220362
Drug: Bupivacain 0.125%/Fentanyl 2mcg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacain 0.125%/Fentanyl 2mcg/ml
Trial: NCT00520234
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 cc IV daily
Trial: NCT03642548
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in control group receive platinum-based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
Trial: NCT00881127
Drug: Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03600376
Drug: Ryanodex and Standard of Care
RxNorm normalized name: Ryanodex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ryanodex to be administered as a rapid IV push
Trial: NCT02546570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions for dosage amount and procedure.
Trial: NCT02496546
Drug: LEO 32731 cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied for 3 weeks
Trial: NCT02496546
Drug: LEO 32731 cream vehicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied for 3 weeks
Trial: NCT04314505
Drug: Opioid-Based Patient Controlled Analgesia
RxNorm normalized name: OPIOID ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a general anesthesia procedure was performed, an experienced anesthesiologist performed ultrasound guided adductor canal block procedures on both knees. The patient was informed that the intravenous bolus of rescue morphine (4mg) was available every 4 hours if the pain was intolerable. In the PCA group, the device was applied before incision and the initial setting was 0.01mg/kg\*hour, patient-controlled dose 2 mg, lock-out 5 minutes and limited 40mg in each 4 hours. After the surgery, the staff of PCA group would visit the patients and adjusted the dosage. The PCA was removed after 72 hours from the surgery. Before the wound closure, the periarticular injection (each side 10 ml of 0.25% Bupivacaine) was done. The total dosage would be recorded in the device. All patients received oral paracetamol 500mg, 4 times a day and oral celecoxib 200mg, 2 times a day after surgery.
Trial: NCT01033305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, once per day for 4 weeks
Trial: NCT04443543
Drug: Capecitabine (Xeloda) Pharmacogenetic Test Reagents
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14
Trial: NCT04443543
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FOLFIRINOX: 400mg/m2 iv d1bolus, 2400mg/m2 ivgtt 46h
Trial: NCT02744820
Drug: GMC-252-L-Lysine Salt
RxNorm normalized name: Lysine acetylcysteinate salt
DrugBank: Nacystelyn (DB17839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose by oral route, once a day, 28 days
Trial: NCT02331433
Drug: APN1125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APN1125 orally at ascending doses
Trial: NCT02331433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT00377377
Drug: EP1572 (ghrelin agonist) oral and duodenal application
RxNorm normalized name: Somatropin and somatropin agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03073980
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Acetaminophen for pain control during procedure
Trial: NCT03073980
Drug: PO Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO Acetaminophen for pain control during procedure
Trial: NCT03476941
Drug: Gentamicin Sulfate Inj 20mg/2ml vial for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigate surgical drain with total amount of 5 mg in 10 ml volume twice/day for 7 days or until drain removal if less than 7 days of therapy.
Trial: NCT01194791
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
Trial: NCT01724372
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01724372
Drug: Antipsychotic
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01616225
Drug: No Saizen Control (Standard IVF Protocol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
Trial: NCT03476941
Drug: Clindamycin phosphate 6 mg/1ml for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigate surgical drain with total amount of 12 mg in 10 ml volume once daily for 7 days or until drain removal if less than 7 days of therapy.
Trial: NCT05069883
Drug: Steroid Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group Oral steroid medication after Direct Vision Internal Urethrotomy
Trial: NCT00000541
Drug: folic acid/Vitamin B6/Vitamin B12
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05069883
Drug: No steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group no Oral steroid medication (palcebo medication) after Direct Vision Internal Urethrotomy
Trial: NCT00538395
Drug: Adriamycin, Taxol and Cytoxan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT01561950
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
Trial: NCT00754793
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive comparator; titrated as per protocol over 12 weeks
Trial: NCT01507051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 0 to 3: 1 tablet placebo, identical to active tablet
Trial: NCT03067753
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01043276
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00258210 220 µg using inhaler A
Trial: NCT01043276
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
Trial: NCT02908256
Drug: Geloplasma (PVI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI\>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
Trial: NCT02908256
Drug: Geloplasma (delta PP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP\> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
Trial: NCT00164112
Drug: Cooperstown 5+1 alone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00164112
Drug: Azithromycin plus Cooperstown 5+1
RxNorm normalized name: azithromycin 1 % Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00164112
Drug: Telithromycin plus Cooperstown 5+1
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00219284
Drug: Carbidopa/levodopa/entacapone
RxNorm normalized name: carbidopa/levodopa/entacapone 25 mg-100 mg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
Trial: NCT03028870
Drug: V120083
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT03028870
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT03028870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules to match V120083 and/or naproxen
Trial: NCT03036085
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
Trial: NCT03805945
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
Trial: NCT02572141
Drug: Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).